The efficacy of ICIs is attributed to their ability to modulate immunity at the tumor site by blocking the PD-1/PD-L1 pathway, thereby enabling immune cells to better eliminate cancer cells within the tumor microenvironment [47,51,53]. The gene discussed is CD274; the disease is cancer.